Mechelen

Galapagos increases share capital through subscription right exercises

Thursday, May 28, 2020 - 9:01pm

Mechelen, Belgium; 28 May 2020, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.

Key Points: 
  • Mechelen, Belgium; 28 May 2020, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises.
  • Galapagos issued 435,540 new ordinary shares on 28 May 2020, for a total capital increase (including issuance premium) of 17,914,162.40.
  • CEO Onno van de Stolpe exercised 40,000 subscription rights.
  • This excludes the 2,280,500 subscription rights of Subscription Right Plan 2020 and Subscription Right Plan 2020 RMV, which were created subject to acceptance.

GILEAD AND GALAPAGOS ANNOUNCE POSITIVE TOPLINE RESULTS OF PHASE 2B/3 TRIAL OF FILGOTINIB IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Wednesday, May 20, 2020 - 8:21pm

Of patients receiving filgotinib 100 mg, 23.8 percent achieved clinical remission at Week 58, compared with 13.5 percent treated with placebo (p=0.0420).

Key Points: 
  • Of patients receiving filgotinib 100 mg, 23.8 percent achieved clinical remission at Week 58, compared with 13.5 percent treated with placebo (p=0.0420).
  • The SELECTION Phase 2b/3 trial is a multi-center, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of the selective JAK1 inhibitor filgotinib in adult patients with moderately to severely active ulcerative colitis.
  • Across both induction studies, patients with moderately to severely active UC were randomized to receive filgotinib 200 mg, filgotinib 100 mg or placebo in a 2:2:1 ratio.
  • Gilead and Galapagos are collaborative partners in the global development and commercialization of filgotinib in inflammatory indications.

On track for clinical read-outs and commercial readiness in 2020

Thursday, May 7, 2020 - 9:03pm

We realized a net loss of 50.6million for the first three months of 2020, compared to a net loss of 48.7million for the first three months of 2019.

Key Points: 
  • We realized a net loss of 50.6million for the first three months of 2020, compared to a net loss of 48.7million for the first three months of 2019.
  • We reported an operating loss amounting to 44.6million for the first three months of 2020, compared to an operating loss of 53.2million for the first three months of 2019.
  • Our R&D expenditure in the first three months of 2020 amounted to 116.8million, compared to 83.2million for the first three months of 2019.
  • Galapagos will conduct a conference call open to the public tomorrow, 08 May 2020, at 14:00CET/8AM ET, which will also be webcasted.

Galapagos creates new subscription right plans

Friday, April 17, 2020 - 9:01pm

On 17 April 2020, the board of directors of Galapagos approved Subscription Right Plan 2020 RMV, intended for the employees of its French subsidiary, Galapagos SASU, and Subscription Right Plan 2020, intended for other members of personnel of the company and its subsidiaries, within the framework of the authorized capital.

Key Points: 
  • On 17 April 2020, the board of directors of Galapagos approved Subscription Right Plan 2020 RMV, intended for the employees of its French subsidiary, Galapagos SASU, and Subscription Right Plan 2020, intended for other members of personnel of the company and its subsidiaries, within the framework of the authorized capital.
  • Under these subscription right plans, 2,280,500 subscription rights were created, subject to acceptances, and offered to the beneficiaries of the plans.
  • Each subscription right gives the right to subscribe to one new Galapagos share.
  • This excludes the 2,280,500 subscription rights of Subscription Right Plan 2020 and Subscription Right Plan 2020 RMV, which were created subject to acceptance.

Important update to Galapagos’ invitation to its ordinary and extraordinary shareholders’ meetings

Friday, April 17, 2020 - 12:04am

4 under special powers published on 9 April 2020, the physical presence of shareholders, proxyholders, holders of subscription rights or other persons otherwise entitled to attend the shareholders meeting will be prohibited at Galapagos annual (ordinary) and extraordinary shareholders meetings scheduled for Tuesday 28 April 2020 at 2:00 p.m. (CET).

Key Points: 
  • 4 under special powers published on 9 April 2020, the physical presence of shareholders, proxyholders, holders of subscription rights or other persons otherwise entitled to attend the shareholders meeting will be prohibited at Galapagos annual (ordinary) and extraordinary shareholders meetings scheduled for Tuesday 28 April 2020 at 2:00 p.m. (CET).
  • Shareholders are kindly invited and strongly encouraged to vote prior to the meetings, either by voting form or by proxy.
  • An updated proxy form is available on our website, under the tab Investors > Shareholder Information > Shareholders Meetings > Proxy form.
  • An updated voting form is available on our website, under the tab Investors > Shareholder Information > Shareholders Meetings > Voting form.

Galapagos and Ryvu announce research collaboration

Thursday, April 16, 2020 - 6:30am

Galapagos cautions the reader that forward-looking statements are not guarantees of future performance.

Key Points: 
  • Galapagos cautions the reader that forward-looking statements are not guarantees of future performance.
  • A further list and description of these risks, uncertainties and other risks can be found in Galapagos Securities and Exchange Commission (SEC) filings and reports, including in Galapagos most recent annual report on Form 20-F filed with the SEC and other filings and reports filed by Galapagos with the SEC.
  • Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.
  • Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology.

Publication of the annual report and invitation to the ordinary and extraordinary shareholders’ meetings

Friday, March 27, 2020 - 8:01pm

The annual report for the financial year 2019, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF.

Key Points: 
  • The annual report for the financial year 2019, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF.
  • Furthermore, Galapagos has the honor to invite its shareholders, holders of subscription rights, directors, and statutory auditor to its annual (ordinary) and extraordinary shareholders meetings that will be held on Tuesday 28 April 2020 at 2:00 p.m. (CET) at the Companys registered office.
  • The convening notice and other documents pertaining to the shareholders meetings, including the biography of Dr. Svanberg, can be consulted on our website, www.glpg.com/shareholders-meetings .
  • Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines.

Galapagos increases share capital through warrant exercises

Tuesday, March 17, 2020 - 8:01pm

Mechelen, Belgium; 17 March 2020, 21.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises.

Key Points: 
  • Mechelen, Belgium; 17 March 2020, 21.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises.
  • Galapagos issued 152,220 new ordinary shares on 17 March 2020, for a total capital increase (including issuance premium) of 5,354,538.80.
  • Pursuant to the warrant exercise program of Galapagos executive committee, executive committee members automatically are committed to exercise a minimum number of warrants, subject to certain conditions.
  • Galapagos does not have any convertible bonds or shares without voting rights outstanding.

Transformational year for Galapagos

Thursday, February 20, 2020 - 9:01pm

After a historic 2019, 2020 promises to be a particularly eventful and exciting year for Galapagos.

Key Points: 
  • After a historic 2019, 2020 promises to be a particularly eventful and exciting year for Galapagos.
  • Galapagos expects to be able to publish its fully audited annual report for the full year 2019 on or around 27 March 2020.
  • Galapagos will conduct a conference call open to the public tomorrow, 21 February 2020, at 14:00 CET/8 AM ET, which will also be webcasted.
  • Galapagos pipeline comprises discovery programs through Phase 3 programs in inflammation, fibrosis, osteoarthritis and other indications.

Orphan Drug Designation for GLPG1690 in systemic sclerosis

Wednesday, January 29, 2020 - 7:00am

Mechelen, Belgium; 29 January 2020, 8.00 CET Galapagos NV (Euronext & NASDAQ: GLPG) announces today that the US Food & Drug Administration (FDA) and the European Commission (EC) have granted investigational autotaxin inhibitor GLPG1690 orphan drug designation for the treatment of systemic sclerosis (SSc).

Key Points: 
  • Mechelen, Belgium; 29 January 2020, 8.00 CET Galapagos NV (Euronext & NASDAQ: GLPG) announces today that the US Food & Drug Administration (FDA) and the European Commission (EC) have granted investigational autotaxin inhibitor GLPG1690 orphan drug designation for the treatment of systemic sclerosis (SSc).
  • Diffuse cutaneous systemic sclerosis (SSc) is an autoimmune disease involving multiorgan fibrosis, which has one of the highest mortality rates among rheumatic diseases.3 One of the most visible manifestions is hardening of the skin.
  • Galapagos identified the autotaxin target using its proprietary target discovery platform and developed molecule GLPG1690 as an inhibitor of this target.
  • GLPG1690 is an investigational drug and its efficacy and safety have not been established by any regulatory agency.